Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

[Aspirin use in cardiovascular disease prevention: a population-based study].

Vianna CA, González DA, Matijasevich A.

Cad Saude Publica. 2012 Jun;28(6):1122-32. Portuguese.

2.

Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients--a longitudinal observational study.

Leung WY, So WY, Stewart D, Lui A, Tong PC, Ko GT, Kong AP, Ma RC, Chan FK, Yang X, Chiang SC, Chan JC.

Cardiovasc Diabetol. 2009 Oct 30;8:57. doi: 10.1186/1475-2840-8-57.

4.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

5.

Aspirin for primary prevention of CVD: are the right people using it?

VanWormer JJ, Greenlee RT, McBride PE, Peppard PE, Malecki KC, Che J, Nieto FJ.

J Fam Pract. 2012 Sep;61(9):525-32.

PMID:
23000660
6.

Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.

Rolka DB, Fagot-Campagna A, Narayan KM.

Diabetes Care. 2001 Feb;24(2):197-201.

PMID:
11213865
7.

Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study.

Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH.

Arch Intern Med. 1994 Dec 12-26;154(23):2649-57.

PMID:
7993148
8.

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304. Epub 2005 Mar 7.

9.

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.

Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group.

Diabetes Care. 2003 Dec;26(12):3264-72.

PMID:
14633812
10.

Use of acetylsalicylic acid by physicians and in the community.

Mahon J, Steel K, Feagan BG, Laupacis A, Pederson LL.

CMAJ. 1991 Nov 1;145(9):1107-16.

11.

The association between socioeconomic indicators and cardiovascular disease risk factors in Rio de Janeiro, Brazil.

Marins VM, Almeida RM, Pereira RA, Sichieri R.

J Biosoc Sci. 2007 Mar;39(2):221-9. Epub 2006 Feb 1.

PMID:
16448583
12.

Prevalence of medical visits and associated factors, Pelotas, Southern Brazil, 1999-2000.

da Costa JS, Reis MC, Silveira Filho CV, Linhares Rda S, Piccinini F.

Rev Saude Publica. 2008 Dec;42(6):1074-84. Epub 2008 Oct 9. English, Portuguese.

13.
14.
15.

[Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests].

Maciá Bobes C, Ronzón Fernández A, Fernández García E.

Rev Esp Salud Publica. 2006 Nov-Dec;80(6):613-20. Review. Spanish.

16.

[Factors associated with interpersonal continuity of care: a population-based study].

Rosa Filho LA, Fassa AG, Paniz VM.

Cad Saude Publica. 2008 Apr;24(4):915-25. Portuguese.

17.
18.

Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.

Bruno A, Grassi G, Dani F, Degiovanni M, Maghenzani G, Pagano G.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):42-6.

PMID:
15871850
19.

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.

Greving JP, Buskens E, Koffijberg H, Algra A.

Circulation. 2008 Jun 3;117(22):2875-83. doi: 10.1161/CIRCULATIONAHA.107.735340. Epub 2008 May 27.

20.

Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian state of Rio de Janeiro.

de Souza LJ, Souto Filho JT, de Souza TF, Reis AF, Gicovate Neto C, Bastos DA, Côrtes VA, Chalita FE, Teixeira CL.

Arq Bras Cardiol. 2003 Sep;81(3):249-64. Epub 2003 Oct 9. English, Portuguese.

Supplemental Content

Support Center